Regenerative med-tech Tissue Regenix (LON:TRX) has appointed the chief executive of Consort Medical to its board as a non-executive.
Jonathan Glenn has run inhaler specialist Consort since 2007 and previously held senior financial roles across the medical industry including seven years at Celltech where he played a key role in the acquisitions of Chiroscience, Medeva and OGS.
John Samuel, Tissue Regenix’s chairman, he was very pleased Glenn was joining the business.
“He has excellent experience in the medical devices market.”
Tissue Regenix has patented a cell-washing technology that it is using to pioneer replacement body parts including skin, knee cartilages, ligaments and heart valves.